Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

KRAS testing in metastatic colorectal carcinoma: challenges, controversies, breakthroughs and beyond.

Malapelle U, Carlomagno C, de Luca C, Bellevicine C, Troncone G.

J Clin Pathol. 2014 Jan;67(1):1-9. doi: 10.1136/jclinpath-2013-201835. Epub 2013 Sep 10. Review.

PMID:
24022727
2.

KRAS mutations testing in colorectal carcinoma patients in Italy: from guidelines to external quality assessment.

Normanno N, Pinto C, Castiglione F, Bardelli A, Gambacorta M, Botti G, Nappi O, Siena S, Ciardiello F, Taddei G, Marchetti A.

PLoS One. 2011;6(12):e29146. doi: 10.1371/journal.pone.0029146. Epub 2011 Dec 21.

3.

Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes.

Pentheroudakis G, Kotoula V, De Roock W, Kouvatseas G, Papakostas P, Makatsoris T, Papamichael D, Xanthakis I, Sgouros J, Televantou D, Kafiri G, Tsamandas AC, Razis E, Galani E, Bafaloukos D, Efstratiou I, Bompolaki I, Pectasides D, Pavlidis N, Tejpar S, Fountzilas G.

BMC Cancer. 2013 Feb 2;13:49. doi: 10.1186/1471-2407-13-49.

4.

A systematic review and meta-analysis of KRAS status as the determinant of response to anti-EGFR antibodies and the impact of partner chemotherapy in metastatic colorectal cancer.

Adelstein BA, Dobbins TA, Harris CA, Marschner IC, Ward RL.

Eur J Cancer. 2011 Jun;47(9):1343-54. doi: 10.1016/j.ejca.2011.03.031. Epub 2011 May 5. Review.

PMID:
21550229
5.

Clinical implementation of KRAS testing in metastatic colorectal carcinoma: the pathologist's perspective.

Ross JS.

Arch Pathol Lab Med. 2012 Oct;136(10):1298-307. Epub 2012 Jan 24. Review.

PMID:
22272560
6.

Concordance in KRAS and BRAF mutations in endoscopic biopsy samples and resection specimens of colorectal adenocarcinoma.

Krol LC, 't Hart NA, Methorst N, Knol AJ, Prinsen C, Boers JE.

Eur J Cancer. 2012 May;48(7):1108-15. doi: 10.1016/j.ejca.2012.02.054. Epub 2012 Mar 23.

PMID:
22446020
7.

Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: beyond KRAS mutations.

Custodio A, Feliu J.

Crit Rev Oncol Hematol. 2013 Jan;85(1):45-81. doi: 10.1016/j.critrevonc.2012.05.001. Epub 2012 May 28. Review.

PMID:
22647972
8.

New strategies for treatment of KRAS mutant metastatic colorectal cancer.

Prenen H, Tejpar S, Van Cutsem E.

Clin Cancer Res. 2010 Jun 1;16(11):2921-6. doi: 10.1158/1078-0432.CCR-09-2029. Epub 2010 May 11. Review.

9.

Uptake of KRAS mutation testing in patients with metastatic colorectal cancer in Europe, Latin America and Asia.

Ciardiello F, Tejpar S, Normanno N, Mercadante D, Teague T, Wohlschlegel B, Van Cutsem E.

Target Oncol. 2011 Sep;6(3):133-45. doi: 10.1007/s11523-011-0181-x. Epub 2011 Jun 1.

PMID:
21630045
10.

[Prognostic role of KRAS mutation in colorectal cancer].

Di Fiore F, Michel P.

Bull Cancer. 2009 Dec;96 Suppl:S23-30. doi: 10.1684/bdc.2009.0994. French.

PMID:
20034867
11.

Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases.

Baldus SE, Schaefer KL, Engers R, Hartleb D, Stoecklein NH, Gabbert HE.

Clin Cancer Res. 2010 Feb 1;16(3):790-9. doi: 10.1158/1078-0432.CCR-09-2446. Epub 2010 Jan 26.

13.

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

Lièvre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, Côté JF, Tomasic G, Penna C, Ducreux M, Rougier P, Penault-Llorca F, Laurent-Puig P.

Cancer Res. 2006 Apr 15;66(8):3992-5.

14.

Genetic analysis of KRAS mutation status in metastatic colorectal cancer patients.

Zavodna K, Konecny M, Krivulcik T, Spanik S, Behulova R, Vizvaryova M, Weismanova E, Galbavy S, Kausitz J.

Neoplasma. 2009;56(3):275-8.

PMID:
19309232
15.

EGFR fluorescence in situ hybridization pattern of chromosome 7 disomy predicts resistance to cetuximab in KRAS wild-type metastatic colorectal cancer patients.

Li YH, Wang F, Shen L, Deng YM, Shao Q, Feng F, An X, Wang FH, Wang ZQ, Xu RH, Shao JY.

Clin Cancer Res. 2011 Jan 15;17(2):382-90. doi: 10.1158/1078-0432.CCR-10-0208. Epub 2010 Sep 30.

16.

EGFR gene copy number assessment from areas with highest EGFR expression predicts response to anti-EGFR therapy in colorectal cancer.

Ålgars A, Lintunen M, Carpén O, Ristamäki R, Sundström J.

Br J Cancer. 2011 Jul 12;105(2):255-62. doi: 10.1038/bjc.2011.223. Epub 2011 Jun 21.

17.

KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients.

Knijn N, Mekenkamp LJ, Klomp M, Vink-Börger ME, Tol J, Teerenstra S, Meijer JW, Tebar M, Riemersma S, van Krieken JH, Punt CJ, Nagtegaal ID.

Br J Cancer. 2011 Mar 15;104(6):1020-6. doi: 10.1038/bjc.2011.26. Epub 2011 Mar 1.

18.

Canadian Expert Group consensus recommendations: KRAS testing in colorectal cancer.

Aubin F, Gill S, Burkes R, Colwell B, Kamel-Reid S, Koski S, Pollett A, Samson B, Tehfe M, Wong R, Young S, Soulières D.

Curr Oncol. 2011 Aug;18(4):e180-4.

19.

How close are we to standardised extended RAS gene mutation testing? The UK NEQAS evaluation.

Richman SD, Fairley J, Butler R, Deans ZC.

J Clin Pathol. 2017 Jan;70(1):58-62. doi: 10.1136/jclinpath-2016-203822. Epub 2016 Sep 28.

20.

Molecular Evaluation of Colorectal Adenocarcinoma: Current Practice and Emerging Concepts.

Nowak JA, Hornick JL.

Surg Pathol Clin. 2016 Sep;9(3):427-39. doi: 10.1016/j.path.2016.04.007. Review.

PMID:
27523970

Supplemental Content

Support Center